275 related articles for article (PubMed ID: 8112891)
1. Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma.
Moser TL; Young TN; Rodriguez GC; Pizzo SV; Bast RC; Stack MS
Int J Cancer; 1994 Feb; 56(4):552-9. PubMed ID: 8112891
[TBL] [Abstract][Full Text] [Related]
2. Proteinase requirements of epidermal growth factor-induced ovarian cancer cell invasion.
Ellerbroek SM; Hudson LG; Stack MS
Int J Cancer; 1998 Oct; 78(3):331-7. PubMed ID: 9766568
[TBL] [Abstract][Full Text] [Related]
3. Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells.
Fishman DA; Bafetti LM; Banionis S; Kearns AS; Chilukuri K; Stack MS
Cancer; 1997 Oct; 80(8):1457-63. PubMed ID: 9338470
[TBL] [Abstract][Full Text] [Related]
4. Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium.
Young TN; Rodriguez GC; Moser TL; Bast RC; Pizzo SV; Stack MS
Am J Obstet Gynecol; 1994 May; 170(5 Pt 1):1285-96. PubMed ID: 8178854
[TBL] [Abstract][Full Text] [Related]
5. Association between alphavbeta6 integrin expression, elevated p42/44 kDa MAPK, and plasminogen-dependent matrix degradation in ovarian cancer.
Ahmed N; Pansino F; Baker M; Rice G; Quinn M
J Cell Biochem; 2002; 84(4):675-86. PubMed ID: 11835393
[TBL] [Abstract][Full Text] [Related]
6. Regulation of plasminogen activation, matrix metalloproteinases and urokinase-type plasminogen activator-mediated extracellular matrix degradation in human osteosarcoma cell line MG63 by interleukin-1 alpha.
de Bart AC; Quax PH; Löwik CW; Verheijen JH
J Bone Miner Res; 1995 Sep; 10(9):1374-84. PubMed ID: 7502710
[TBL] [Abstract][Full Text] [Related]
7. Characterization of matrix-degrading proteinases and their inhibitors secreted by human gynecological carcinoma cells.
Miyagi E; Yasumitsu H; Hirahara F; Minaguchi H; Koshikawa N; Miyazaki K; Umeda M
Jpn J Cancer Res; 1995 Jun; 86(6):568-76. PubMed ID: 7622422
[TBL] [Abstract][Full Text] [Related]
8. Urokinase-mediated extracellular matrix degradation by human prostatic carcinoma cells and its inhibition by retinoic acid.
Webber MM; Waghray A
Clin Cancer Res; 1995 Jul; 1(7):755-61. PubMed ID: 9816042
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.
Festuccia C; Dolo V; Guerra F; Violini S; Muzi P; Pavan A; Bologna M
Clin Exp Metastasis; 1998 Aug; 16(6):513-28. PubMed ID: 9872599
[TBL] [Abstract][Full Text] [Related]
10. Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2.
Young TN; Rodriguez GC; Rinehart AR; Bast RC; Pizzo SV; Stack MS
Gynecol Oncol; 1996 Jul; 62(1):89-99. PubMed ID: 8690299
[TBL] [Abstract][Full Text] [Related]
11. Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells.
Rosanò L; Varmi M; Salani D; Di Castro V; Spinella F; Natali PG; Bagnato A
Cancer Res; 2001 Nov; 61(22):8340-6. PubMed ID: 11719468
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen activation by t-PA on the surface of human melanoma cells in the presence of alpha 2-macroglobulin secretion.
Bizik J; Lizonová A; Stephens RW; Grófová M; Vaheri A
Cell Regul; 1990 Nov; 1(12):895-905. PubMed ID: 1712633
[TBL] [Abstract][Full Text] [Related]
13. Mouse trophoblastic cell lines: II--Relationship between invasive potential and proteases.
Sharma RK
In Vivo; 1998; 12(2):209-17. PubMed ID: 9627804
[TBL] [Abstract][Full Text] [Related]
14. Modulation of murine B16F10 melanoma plasminogen activator production by a synthetic peptide derived from the laminin A chain.
Stack MS; Gray RD; Pizzo SV
Cancer Res; 1993 May; 53(9):1998-2004. PubMed ID: 8481902
[TBL] [Abstract][Full Text] [Related]
15. Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants.
Stephens RW; Pöllänen J; Tapiovaara H; Leung KC; Sim PS; Salonen EM; Rønne E; Behrendt N; Danø K; Vaheri A
J Cell Biol; 1989 May; 108(5):1987-95. PubMed ID: 2523891
[TBL] [Abstract][Full Text] [Related]
16. Vascular extracellular matrix remodeling in cerebral aneurysms.
Bruno G; Todor R; Lewis I; Chyatte D
J Neurosurg; 1998 Sep; 89(3):431-40. PubMed ID: 9724118
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen activator and matrix metalloproteinase production and extracellular matrix degradation by rat prostate cancer cells in vitro: correlation with metastatic behavior in vivo.
Quax PH; de Bart AC; Schalken JA; Verheijen JH
Prostate; 1997 Aug; 32(3):196-204. PubMed ID: 9254899
[TBL] [Abstract][Full Text] [Related]
18. Regulation of gelatinase activity in mice with targeted inactivation of components of the plasminogen/plasmin system.
Lijnen HR; Silence J; Lemmens G; Frederix L; Collen D
Thromb Haemost; 1998 Jun; 79(6):1171-6. PubMed ID: 9657444
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen activator secretion by established lines of human ovarian carcinoma cells in vitro.
Karlan BY; Amin W; Band V; Zurawski VR; Littlefield BA
Gynecol Oncol; 1988 Sep; 31(1):103-12. PubMed ID: 3410341
[TBL] [Abstract][Full Text] [Related]
20. Degradation of extracellular matrix by metastatic follicular thyroid carcinoma cell lines: role of the plasmin activation system.
Smit JW; van der Pluijm G; Romijn HA; Löwik CW; Morreau H; Goslings BM
Thyroid; 1999 Sep; 9(9):913-9. PubMed ID: 10524570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
